In this webinar, we'll discuss how mobile apps are changing the healthcare journey for patients and visitors from all walks of life.
NICE greenlights Harvoni for Britain's national formulary, Pacria received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.
Analysts say head-to-head study results could make Kyprolis the lead treatment.
Drugmakers face increasing pressure on pricing from insurers and PBMs.
The breakthrough designation therapy drug was the first for its drug class.
Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.
Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.
Session: Battle of the Big Idea
Session: Intelligent Connections
A monthly showcase of companies offering expertise, experience and services within specific areas of the industry. In this edition: multichannel marketing
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Poll shows all ages seek digital health tools
- Survey shows docs overestimate adherence
- Drugmaker shifts sales model to keep pace with formulary decision making
- Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence
- Global cancer drug market to grow to $111 billion by 2020: report